Stronger Warnings for Gadolinium-Based Contrast Agents
The Food and Drug Administration has requested that makers of all gadolinium-based contrast agents (GBCAs) add new warnings, including a "black box" warning about the risk of nephrogenic systemic fibrosis (NSF). Brand names affected by the new warnings include: Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance. A black box warning is the strongest warning the FDA can mandate.
Continue reading "Stronger Warnings for Gadolinium-Based Contrast Agents" »
